Enzo Biochem (Enzo Biochem) Days Payable : 34.57 (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Days Payable?

Enzo Biochem's average Accounts Payable for the three months ended in Jan. 2024 was $1.64 Mil. Enzo Biochem's Cost of Goods Sold for the three months ended in Jan. 2024 was $4.33 Mil. Hence, Enzo Biochem's Days Payable for the three months ended in Jan. 2024 was 34.57.

The historical rank and industry rank for Enzo Biochem's Days Payable or its related term are showing as below:

During the past 13 years, Enzo Biochem's highest Days Payable was 112.45. The lowest was 47.30. And the median was 58.05.

ENZ's Days Payable is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 68.79
* Ranked among companies with meaningful Days Payable only.

Enzo Biochem's Days Payable declined from Jan. 2023 (210.51) to Jan. 2024 (34.57). It may suggest that Enzo Biochem accelerated paying its suppliers.

Enzo Biochem Days Payable Historical Data

The historical data trend for Enzo Biochem's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Days Payable Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Days Payable

Get a 7-Day Free Trial

52.85

55.04

47.30

112.45

68.24

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Days Payable	Get a 7-Day Free Trial															210.51	84.62	-	58.06	34.57

Competitive Comparison of Enzo Biochem's Days Payable

For the Diagnostics & Research subindustry, Enzo Biochem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzo Biochem's Days Payable Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Days Payable distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Days Payable falls into.

Enzo Biochem Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Enzo Biochem's Days Payable for the fiscal year that ended in Jul. 2023 is calculated as

	Days Payable (A: Jul. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jul. 2022 )	+	Accounts Payable (A: Jul. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jul. 2023 )	*	Days in Period
=	( (3.715	+	3.575)	/	2 )	/	19.495	*	365
=	3.645					/	19.495	*	365
=	68.24

Enzo Biochem's Days Payable for the quarter that ended in Jan. 2024 is calculated as:

	Days Payable (Q: Jan. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Oct. 2023 )	+	Accounts Payable (Q: Jan. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jan. 2024 )	*	Days in Period
=	( (1.962	+	1.318)	/	2 )	/	4.329	*	365 / 4
=	1.64					/	4.329	*	365 / 4
=	34.57

Enzo Biochem Days Payable Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (Enzo Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Days Payable

Comparable Companies

PRE DRIO PSNL AWH BIOQ MDXH OCX VNRX BIAF TTOO TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

EZB:Germany

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Executives

Steven J Pully	director	9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf	10 percent owner	105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian	officer: Chief Executive Officer	527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert	officer: Interim CFO	C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon	officer: Chief Operating Officer	527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff	director	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench	officer: CHIEF FINANCIAL OFFICER	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp	10 percent owner	HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri	director	455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv	10 percent owner	2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank	10 percent owner, other: See Remarks	ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203